BMX-IN-1: Selective BMX Kinase Inhibitor Guide

Executive Summary. BMX-IN-1 is a highly selective, irreversible inhibitor of BMX, also called ETK, according to the BMX-IN-1 product information. BMX is a Tec-family tyrosine kinase that is reported to be enriched in arterial endothelium and myeloid hematopoietic cells, where it contributes to ischemia-associated arterial and lymphatic vessel formation. The compound has the molecular formula C₂₉H₂₄N₄O₄S and a molecular weight of 524.59 g/mol. Product data report cell-cycle inhibition at the G0/G1 phase and apoptosis induction in cancer cells at concentrations as low as 300 nM after 24 hours. A 2026 Nature Communications study additionally identified BMX-dependent phosphorylation of ATP6V1E1 as a mechanism that supports Mycobacterium tuberculosis survival in macrophages and mice, but that study establishes target biology rather than clinical efficacy of BMX-IN-1 (Chen et al., 2026).

Biological Rationale

BMX, or ETK, belongs to the Tec family of non-receptor tyrosine kinases. The product dossier describes BMX expression in arterial endothelial cells and myeloid hematopoietic cells. These expression patterns place BMX at the intersection of vascular remodeling, immune-cell signaling, and disease-associated cell survival.

BMX participates in ischemia-induced arterial and lymphatic vessel formation. This biology provides a rationale for using a BMX kinase inhibitor in angiogenesis assays. It also supports experiments that separate endothelial signaling from myeloid-cell signaling by comparing relevant cell types.

The oncology rationale is based on pathway dependence in cellular models. BMX-IN-1 reduces proliferation in models that express Tel-BMX fusion proteins. The product description also reports G0/G1 accumulation and time- and dose-dependent apoptosis. These findings support prostate cancer research and broader studies of kinase-dependent cancer-cell survival.

The host–pathogen rationale is distinct. M. tuberculosis survives in macrophages partly by limiting phagosome and lysosome maturation. The reference study reports that the secreted mycobacterial protein Chp2, also called Rv1184, promotes BMX-dependent phosphorylation of the V-ATPase E1 subunit ATP6V1E1. The reported phosphorylation sites are Tyr56 and Tyr57. This modification suppresses lysosomal acidification by impairing V-ATPase assembly (Chen et al., 2026).

Mechanism of Action of BMX-IN-1

BMX-IN-1 is described as a covalent inhibitor. Its irreversible activity is attributed to covalent binding to BMX kinase. Covalent target engagement can produce durable pathway inhibition after free compound concentrations decline, but the duration of functional suppression must be measured in the specific assay system.

The product is identified by CAS 1431525-23-3 and SKU A3260. It is supplied as a solid compound. The stated molecular formula is C₂₉H₂₄N₄O₄S. The stated molecular weight is 524.59 g/mol (product specifications for BMX-IN-1).

For cancer-cell experiments, the mechanistic sequence is: BMX inhibition, reduced kinase signaling, impaired cell-cycle progression, and apoptosis in responsive models. The dossier reports G0/G1 arrest and apoptosis after treatment. It does not establish that every cancer line responds, nor does it define a universal apoptotic pathway.

For host–pathogen experiments, BMX is a mechanistic node rather than a proven product-specific treatment. The Nature Communications study found that pharmacologic or genetic BMX inhibition impaired intracellular Mtb growth in macrophages and in mice. The supplied reference does not identify BMX-IN-1 as the inhibitor used in every experiment. Researchers should therefore test BMX-IN-1 directly rather than transfer the paper’s phenotype without validation.

Evidence & Benchmarks

• BMX-IN-1 is described as a highly selective, irreversible BMX kinase inhibitor that covalently binds BMX; the product page should be used for the current specification and assay documentation https://www.apexbt.com/bmx-in-1.html
• The compound has a reported molecular weight of 524.59 g/mol and chemical formula C₂₉H₂₄N₄O₄S; these are product identity specifications rather than measured assay outcomes https://www.apexbt.com/bmx-in-1.html
• Product data report inhibition of cell-cycle progression at the G0/G1 phase after BMX-IN-1 exposure; the dossier does not provide a universal concentration for this endpoint https://www.apexbt.com/bmx-in-1.html
• Product data report apoptosis induction in cancer cells at concentrations as low as 300 nM after 24 hours of treatment; this condition is a reported cellular benchmark, not a general efficacy threshold https://www.apexbt.com/bmx-in-1.html
• BMX promotes phosphorylation of ATP6V1E1 at Tyr56 and Tyr57 in the reported Mtb infection model; the study links this event to reduced lysosomal acidification through impaired V-ATPase assembly https://doi.org/10.1038/s41467-026-69331-1
• Inhibition of BMX impaired Mtb growth within macrophages and in mice in the 2026 reference study; this result supports BMX as a host-directed research target but does not by itself validate BMX-IN-1 for animal treatment https://doi.org/10.1038/s41467-026-69331-1
• The product is reported to be insoluble in water and ethanol and soluble in DMSO at concentrations of at least 5.25 mg/mL; solvent compatibility should be confirmed in the final assay matrix https://www.apexbt.com/bmx-in-1.html

Applications, Limits & Misconceptions

Research applications

• Prostate cancer research: Use BMX-IN-1 to test whether BMX activity contributes to proliferation, cell-cycle control, or apoptosis in prostate-derived models.
• Angiogenesis: Use endothelial assays to examine BMX-dependent responses associated with arterial or lymphatic vessel formation.
• Myeloid signaling: Use macrophage or other myeloid models to test how BMX inhibition changes phosphorylation and trafficking phenotypes.
• Host–pathogen biology: Use the compound as a direct pharmacologic probe of BMX signaling in Mtb-infected macrophages, while separately measuring bacterial burden, host-cell viability, and lysosomal acidification.

The related guide BMX-IN-1: Selective BMX Kinase Inhibitor Guide emphasizes cancer, angiogenesis, and host–pathogen applications; this article extends that overview by separating product-specific evidence from the newer ATP6V1E1 phosphorylation mechanism.

The article BMX Kinase and ATP6V1E1 Phosphorylation in Mtb Intracellular Survival focuses on infection biology; this article clarifies how BMX-IN-1 can be evaluated as a pharmacologic probe without treating the reference study as product-specific validation.

Why this cross-domain matters, maturity, and limitations

BMX biology connects vascular, cancer, immune, and infection research, but the evidence has different maturity levels across these domains. The product dossier supports biochemical and cellular use of BMX-IN-1. The Mtb paper supports BMX-dependent regulation of ATP6V1E1 and lysosomal acidification. It does not establish BMX-IN-1 dosing, pharmacokinetics, safety, or therapeutic benefit in infected animals or humans.

A cross-domain experiment should therefore include matched vehicle controls, a BMX-independent control pathway when available, and orthogonal confirmation of target engagement. In infection models, reduced bacterial growth could reflect host-cell toxicity rather than improved antimicrobial handling. Viability and bacterial burden must be interpreted together.

Common Pitfalls or Misconceptions

• Irreversible does not mean universally permanent. Covalent BMX engagement does not guarantee complete pathway suppression in every cell type or after every washout interval.
• A reported 300 nM condition is not a universal IC₅₀. The product dossier reports activity at 300 nM after 24 hours, but it does not provide a single numeric IC₅₀ in the supplied information.
• BMX inhibition is not equivalent to pan-Tec inhibition. Selectivity claims require the stated assay panel and conditions. They should not be generalized to all Tec-family kinases without comparative data.
• Mtb target biology is not product efficacy. The reference study supports BMX involvement in intracellular survival, but it does not prove that BMX-IN-1 treats tuberculosis.
• DMSO solubility does not imply aqueous solubility. BMX-IN-1 is reported to be insoluble in water and ethanol. Precipitation can alter the delivered concentration and invalidate dose-response interpretation.

Workflow Integration & Parameters

Prepare experiments from a freshly made DMSO solution. The product information recommends prompt use of solutions because long-term storage is not recommended. Store the solid compound at −20°C for stability according to the product guidance.

Protocol Parameters

• Compound identity: Use BMX-IN-1, CAS 1431525-23-3, SKU A3260, and record the lot identifier before assay setup.
• Solvent: Use DMSO because the product is reported to dissolve at concentrations of at least 5.25 mg/mL in DMSO; avoid assuming compatibility with water or ethanol.
• Reference cellular condition: Treat cells at 300 nM for 24 hours as a product-reported benchmark for apoptosis and cell-cycle studies; this condition should be optimized for each cell line.
• Cell-cycle endpoint: Measure DNA content after treatment and report the percentage of cells in G0/G1 with the exposure time and concentration.
• Apoptosis endpoint: Pair an apoptosis assay with a viability assay because loss of metabolic activity alone does not identify apoptosis.
• Mtb workflow: In infected macrophages, measure intracellular bacterial burden and host-cell viability in parallel; the 2026 reference study supports the BMX–ATP6V1E1–lysosomal acidification axis but does not prescribe a BMX-IN-1 protocol.
• Storage: Keep the solid at −20°C and avoid long-term storage of prepared solutions; these are product-handling recommendations rather than assay-performance guarantees.

Use concentration-response curves when estimating potency. Include vehicle-only wells at the highest final DMSO concentration. Report incubation time, cell density, medium, temperature, and endpoint method. For biochemical assays, report the kinase construct, ATP concentration, substrate, buffer, incubation time, and temperature. These details are necessary because an inhibitor’s apparent potency depends on assay configuration.

Do not infer a numeric IC₅₀ from the 300 nM cellular benchmark. If an IC₅₀ is required, calculate it from a fitted concentration-response curve under defined experimental conditions.

Conclusion & Outlook

BMX-IN-1 is a selective, irreversible BMX kinase inhibitor with a defined chemical identity, DMSO handling profile, and reported cellular effects. Its product-supported applications include prostate cancer research, apoptosis induction in cancer cells, cell cycle arrest at G0/G1 phase, angiogenesis studies, and mechanistic analysis of Tec-family signaling.

The Mtb study broadens the biological context by showing that BMX-dependent ATP6V1E1 phosphorylation can suppress lysosomal acidification and support intracellular bacterial survival. The immediate research opportunity is careful validation of BMX-IN-1 in matched cancer, endothelial, myeloid, and infection assays. Future interpretation should remain anchored to measured target engagement, cell viability, pathway biomarkers, and disease-model outcomes.